TRVN—I don’t see a “threading the needle” problem; to the contrary, it seems that TRV130 can be positioned as either a faster-acting more efficacious drug than morphine or a safer drug than morphine. The most consequential safety/tolerability issue is respiratory distress, not nausea.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.